Becton Dickinson and Company (BDX) 177.88 $BDX
Post# of 273249
Posted On: 09/06/2016 11:11:15 PM
Becton Dickinson and Company (BDX) 177.88 $BDX
BD to Present at the Morgan Stanley Global Healthcare Conference 2016
PR Newswire - Tue Sep 06, 7:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2016 on Tuesday, September 13, 2016, at 10:35 a.m. EDT.
BDX: 177.88 (+0.56)
BD Submits Pre-Market Approval Application to FDA for BD Onclarity(TM) HPV Test
PR Newswire - Tue Sep 06, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the BD Onclarity(TM) HPV Assay, its human papillomavirus (HPV) test.
BDX: 177.88 (+0.56)
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 10:13AM CDT
Shares of Becton, Dickinson and Company (BDX) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21.
BABY: 42.11 (+1.47), BDX: 177.88 (+0.56), MASI: 59.54 (-0.36), NUVA: 66.44 (-0.30)
Mayo Clinic Proceedings Publishes New Insulin Injection and Infusion Recommendations
PR Newswire Europe - Thu Sep 01, 7:59AM CDT
New Recommendations Based on Findings from Largest-Ever International Survey of more than 13,200 Insulin-Injecting Patients from 42 Countries
BDX: 177.88 (+0.56)
BD Celebrates 60 Years In Sandy, Utah
PR Newswire - Thu Aug 18, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined by senior public officials today to celebrate the 60th anniversary of its manufacturing facility in Sandy, Utah. BD also announced that it recently approved a $20 million investment in the BD Sandy site as part of its broader plan to invest in manufacturing capacity and support anticipated growth in the catheter solutions platform.
BDX: 177.88 (+0.56)
BD Cited As Infusion Pump EMR Integration Leader In KLAS Report
PR Newswire - Tue Aug 16, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Alaris(TM) System infusion platform was cited as having the most customers live with bidirectional electronic medical record (EMR) integration, which health care providers said is the most important next step for improving safety to help reduce pump-programming errors in the Smart Pumps 2016: The Quest for Patient Safety report issued by KLAS.
BDX: 177.88 (+0.56)
Medtronic Launches MiniMed 630G, Expands in Diabetic Care (revised)
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 4:34PM CDT
The MiniMed 630G basically combines SmartGuard technology which is already featured in the MiniMed 530G system with a brand new user-friendly design.
ABT: 42.16 (+0.07), BDX: 177.88 (+0.56), DXCM: 94.28 (+2.19), MDT: 87.17 (-0.15)
Medtronic Launches MiniMed 630G, Expands in Diabetic Care
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 9:15AM CDT
Medtronic plc's (MDT) MiniMed 630G system with SmartGuard technology recently won the U.S. FDA approval for its commercial launch.
ABT: 42.16 (+0.07), BDX: 177.88 (+0.56), DXCM: 94.28 (+2.19), MDT: 87.17 (-0.15)
Top 4 Research Reports for August 11, 2016
Sheraz Mian - Zacks Investment Research - Thu Aug 11, 11:40AM CDT
Top 4 Research Reports for August 11, 2016
BDX: 177.88 (+0.56), FOXA: 24.42 (-0.13), PSA: 224.37 (-2.42), SO: 52.13 (+0.33), PCLN: 1,436.96 (+14.11), TWX: 78.39 (-0.14)
Becton Dickinson Falls 3.68% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Aug 04, 11:54AM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $166.35 to a high of $169.32. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $174.30 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 177.88 (+0.56)
Watch for Becton Dickinson to Potentially Rebound After Falling 3.68% Yesterday
Comtex SmarTrend(R) - Thu Aug 04, 11:52AM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $166.35 to a high of $169.32. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $174.30 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 177.88 (+0.56)
Becton, Dickinson (BDX) Tops Q3 Earnings, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:02AM CDT
Becton, Dickinson and Company (BDX), reported third-quarter fiscal 2016 earnings of $2.35 per share, which beat the Zacks Consensus Estimate by 16 cents.
HYH: 36.65 (+0.08), BDX: 177.88 (+0.56), ALGN: 95.26 (-0.52), MMSI: 24.44 (-0.05)
Becton, Dickinson (BDX) Beats Q3 Earnings & Revenues
Aniruddha Ganguly - Zacks Investment Research - Thu Aug 04, 6:26AM CDT
Becton, Dickinson???s (BDX) adjusted earnings of $2.35 per share beat the Zacks Consensus Estimate by 16 cents.
BDX: 177.88 (+0.56)
BD Announces Results For 2016 Third Fiscal Quarter
PR Newswire - Thu Aug 04, 5:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced quarterly revenues of $3.198 billion, as reported, for the third fiscal quarter ended June 30, 2016, an increase of 2.5 percent over the prior-year period revenues as reported. On a comparable, currency-neutral basis, third quarter organic adjusted revenues grew 4.0 percent.
BDX: 177.88 (+0.56)
Dental Stocks Releasing Earnings on Aug 4: BDX, HSIC, VWR
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:16AM CDT
For the rest of Q2, earnings for Medical companies are expected to rise 3.4%. Dentistry, a niche industry within the broader Medical sector, holds a lot of potential at this moment.
BDX: 177.88 (+0.56), VWR: 26.74 (-1.05), HSIC: 164.31 (+0.02)
Becton Dickinson (BDX) Breaks Through Support at $175.25
Comtex SmarTrend(R) - Mon Aug 01, 8:48AM CDT
Shares of Becton Dickinson (NYSE:BDX) opened today below their pivot of $176.12 and have already reached the first level of support at $175.25. Investors may be interested in a cross of the next downside pivot targets of $174.51 and $172.90.
BDX: 177.88 (+0.56)
Becton Dickinson Has Returned 23.6% Since SmarTrend Recommendation (BDX)
Comtex SmarTrend(R) - Fri Jul 29, 1:57PM CDT
SmarTrend identified an Uptrend for Becton Dickinson (NYSE:BDX) on February 17th, 2016 at $143.14. In approximately 5 months, Becton Dickinson has returned 23.55% as of today's recent price of $176.85.
BDX: 177.88 (+0.56)
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.88 (+0.56), ANIP: 61.55 (+1.69), GLYC: 7.33 (+0.08), NKTR: 18.93 (+0.48)
BD Names R. Andrew Eckert To Board Of Directors
PR Newswire - Thu Jul 28, 3:15PM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that R. Andrew "Andy" Eckert has been appointed to the company's Board of Directors, effective Sept. 26, bringing the total number of directors to 13.
BDX: 177.88 (+0.56), MDSY: 1.30 (-0.08)
BD to Present at the Morgan Stanley Global Healthcare Conference 2016
PR Newswire - Tue Sep 06, 7:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2016 on Tuesday, September 13, 2016, at 10:35 a.m. EDT.
BDX: 177.88 (+0.56)
BD Submits Pre-Market Approval Application to FDA for BD Onclarity(TM) HPV Test
PR Newswire - Tue Sep 06, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the BD Onclarity(TM) HPV Assay, its human papillomavirus (HPV) test.
BDX: 177.88 (+0.56)
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 10:13AM CDT
Shares of Becton, Dickinson and Company (BDX) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21.
BABY: 42.11 (+1.47), BDX: 177.88 (+0.56), MASI: 59.54 (-0.36), NUVA: 66.44 (-0.30)
Mayo Clinic Proceedings Publishes New Insulin Injection and Infusion Recommendations
PR Newswire Europe - Thu Sep 01, 7:59AM CDT
New Recommendations Based on Findings from Largest-Ever International Survey of more than 13,200 Insulin-Injecting Patients from 42 Countries
BDX: 177.88 (+0.56)
BD Celebrates 60 Years In Sandy, Utah
PR Newswire - Thu Aug 18, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined by senior public officials today to celebrate the 60th anniversary of its manufacturing facility in Sandy, Utah. BD also announced that it recently approved a $20 million investment in the BD Sandy site as part of its broader plan to invest in manufacturing capacity and support anticipated growth in the catheter solutions platform.
BDX: 177.88 (+0.56)
BD Cited As Infusion Pump EMR Integration Leader In KLAS Report
PR Newswire - Tue Aug 16, 5:59AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Alaris(TM) System infusion platform was cited as having the most customers live with bidirectional electronic medical record (EMR) integration, which health care providers said is the most important next step for improving safety to help reduce pump-programming errors in the Smart Pumps 2016: The Quest for Patient Safety report issued by KLAS.
BDX: 177.88 (+0.56)
Medtronic Launches MiniMed 630G, Expands in Diabetic Care (revised)
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 4:34PM CDT
The MiniMed 630G basically combines SmartGuard technology which is already featured in the MiniMed 530G system with a brand new user-friendly design.
ABT: 42.16 (+0.07), BDX: 177.88 (+0.56), DXCM: 94.28 (+2.19), MDT: 87.17 (-0.15)
Medtronic Launches MiniMed 630G, Expands in Diabetic Care
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 9:15AM CDT
Medtronic plc's (MDT) MiniMed 630G system with SmartGuard technology recently won the U.S. FDA approval for its commercial launch.
ABT: 42.16 (+0.07), BDX: 177.88 (+0.56), DXCM: 94.28 (+2.19), MDT: 87.17 (-0.15)
Top 4 Research Reports for August 11, 2016
Sheraz Mian - Zacks Investment Research - Thu Aug 11, 11:40AM CDT
Top 4 Research Reports for August 11, 2016
BDX: 177.88 (+0.56), FOXA: 24.42 (-0.13), PSA: 224.37 (-2.42), SO: 52.13 (+0.33), PCLN: 1,436.96 (+14.11), TWX: 78.39 (-0.14)
Becton Dickinson Falls 3.68% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Aug 04, 11:54AM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $166.35 to a high of $169.32. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $174.30 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 177.88 (+0.56)
Watch for Becton Dickinson to Potentially Rebound After Falling 3.68% Yesterday
Comtex SmarTrend(R) - Thu Aug 04, 11:52AM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $166.35 to a high of $169.32. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $174.30 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 177.88 (+0.56)
Becton, Dickinson (BDX) Tops Q3 Earnings, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:02AM CDT
Becton, Dickinson and Company (BDX), reported third-quarter fiscal 2016 earnings of $2.35 per share, which beat the Zacks Consensus Estimate by 16 cents.
HYH: 36.65 (+0.08), BDX: 177.88 (+0.56), ALGN: 95.26 (-0.52), MMSI: 24.44 (-0.05)
Becton, Dickinson (BDX) Beats Q3 Earnings & Revenues
Aniruddha Ganguly - Zacks Investment Research - Thu Aug 04, 6:26AM CDT
Becton, Dickinson???s (BDX) adjusted earnings of $2.35 per share beat the Zacks Consensus Estimate by 16 cents.
BDX: 177.88 (+0.56)
BD Announces Results For 2016 Third Fiscal Quarter
PR Newswire - Thu Aug 04, 5:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced quarterly revenues of $3.198 billion, as reported, for the third fiscal quarter ended June 30, 2016, an increase of 2.5 percent over the prior-year period revenues as reported. On a comparable, currency-neutral basis, third quarter organic adjusted revenues grew 4.0 percent.
BDX: 177.88 (+0.56)
Dental Stocks Releasing Earnings on Aug 4: BDX, HSIC, VWR
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:16AM CDT
For the rest of Q2, earnings for Medical companies are expected to rise 3.4%. Dentistry, a niche industry within the broader Medical sector, holds a lot of potential at this moment.
BDX: 177.88 (+0.56), VWR: 26.74 (-1.05), HSIC: 164.31 (+0.02)
Becton Dickinson (BDX) Breaks Through Support at $175.25
Comtex SmarTrend(R) - Mon Aug 01, 8:48AM CDT
Shares of Becton Dickinson (NYSE:BDX) opened today below their pivot of $176.12 and have already reached the first level of support at $175.25. Investors may be interested in a cross of the next downside pivot targets of $174.51 and $172.90.
BDX: 177.88 (+0.56)
Becton Dickinson Has Returned 23.6% Since SmarTrend Recommendation (BDX)
Comtex SmarTrend(R) - Fri Jul 29, 1:57PM CDT
SmarTrend identified an Uptrend for Becton Dickinson (NYSE:BDX) on February 17th, 2016 at $143.14. In approximately 5 months, Becton Dickinson has returned 23.55% as of today's recent price of $176.85.
BDX: 177.88 (+0.56)
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.88 (+0.56), ANIP: 61.55 (+1.69), GLYC: 7.33 (+0.08), NKTR: 18.93 (+0.48)
BD Names R. Andrew Eckert To Board Of Directors
PR Newswire - Thu Jul 28, 3:15PM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that R. Andrew "Andy" Eckert has been appointed to the company's Board of Directors, effective Sept. 26, bringing the total number of directors to 13.
BDX: 177.88 (+0.56), MDSY: 1.30 (-0.08)
(0)
(0)Scroll down for more posts ▼